



DOCKET NO.: CELG-0422

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Jerome B. Zeldis, et al.

Confirmation No.: 8455

Application No.: 10/820,397

Group Art Unit: 1614

Filing Date: April 8, 2004

Examiner: Not Yet Assigned

For: **METHODS FOR TREATMENT OF COGNITIVE AND MENOPAUSAL  
DISORDERS WITH D-THREO METHYLPHENIDATE**

DATE OF DEPOSIT: *January 7, 2005*

I HEREBY CERTIFY THAT THIS PAPER IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID,  
ON THE DATE INDICATED ABOVE AND IS  
ADDRESSED TO THE UNITED STATES PATENT AND  
TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA,  
VA 22313-1450

*Elizabeth A. McLoud*

TYPED NAME: Elizabeth A. McLoud

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

- ☒ Copies of reference numbers **100 – 115 and 129 - 142** listed on the attached Form PTO-1449 are enclosed herewith.

- ☒ Copies of reference numbers **116 - 128** on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).

- ☐ Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number \_\_\_\_\_, filed \_\_\_\_\_ for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

- ☐ The relevance of those listed references which are not in the English language is as follows:

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date:

*Jan 6, 2005*



Walter C. Frank

Registration No. 52,911

WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. CELG-0422	Application No. 10/820,397
		Applicant Jerome B. Zeldis, et al.	
		Filing Date April 8, 2004	Group 1614
		Confirmation No. 8455	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
/D.S./	100	Aoyama, T., et al., Gas chromatographic-mass spectrometric analysis of <i>threo</i> -methylphenidate enantiomers in plasma," <i>J. Chromatography</i> , <b>1989</b> , 494, 420-423	
	101	Axten, J.M., et al., "A stereoselective synthesis of <i>dl</i> - <i>threo</i> -methylphenidate: preparation and biological evaluation of novel analogues," <i>J. Org. Chem.</i> , <b>1998</b> , 63, 9628-9629	
	102	Axten, J.M., et al., "Enantioselective synthesis of <i>D</i> - <i>threo</i> -methylphenidate," <i>J. Am. Chem. Soc.</i> , <b>1999</b> , 121, 6511-6512	
	103	Davies, H.M.L., et al., "Highly regio-, diastereo-, and enantioselective C - H insertions of methyl aryldiazoacetates into cyclic N-boc-protected amines, asymmetric synthesis of novel C <sub>2</sub> -symmetric amines and <i>threo</i> -methylphenidate," <i>J. Am. Chem. Soc.</i> , <b>1999</b> , 121, 6509-6510	
	104	Deutsch, H.M., et al., "Synthesis and pharmacology of potential cocaine antagonists. 2. Structure-activity relationship studies of aromatic ring-substituted methylphenidate analogs," <i>J. Med. Chem.</i> , <b>1996</b> , 39, 1201-1209	
	105	Hubbard, J.W., et al., "Enantioselective aspects of the disposition of <i>dl</i> - <i>threo</i> -methylphenidate after the administration of a sustained-release formulation to children with attention deficit-hyperactivity disorder," <i>J of Pharm. Sci.</i> , <b>1989</b> , 78(11), 944-947	
	106	Dirksen, S.J.H., et al., "A postmarketing clinical experience study of Metadata® CD," <i>Curr. Med. Res. And Opinion</i> , <b>2002</b> , 18(7), 371-380	
	107	Lim, H.K., "Enantiomeric resolution of <i>dl</i> - <i>threo</i> -methylphenidate, U.S.P. (Ritalin®), by high-performance liquid chromatography," <i>J. of Chromatography</i> , <b>1985</b> , 378-386	
	108	Matsumura, Y., et al., "A convenient method for synthesis of enantiomerically enriched methylphenidate from <i>N</i> -methoxycarbonylpiperidine," <i>Organic Letters</i> , <b>1999</b> , 1(2), 175-178	
	109	Naito, T., et al., "Rearrangement of sulfonamide derivatives. V. Syntheses of methyl $\alpha$ -phenyl-2- and 4-piperidineacetate," <i>Chem. Pharm. Bull.</i> , <b>1964</b> , 12(5), 588-590	
/D.S./	110	Panizzon, L., "Preparation of pyridyl- and piperidylarylacetonitriles and some derivatives," <i>Helvetica Chimica Acta</i> , <b>1944</b> , 27, 1748-1756	
EXAMINER		/Darryl Sutton/	DATE CONSIDERED 03/14/2008

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. CELG-0422	Application No. 10/820,397
		Applicant Jerome B. Zeldis, et al.	
		Filing Date April 8, 2004	Group 1614
		Confirmation No. 8455	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
/D.S./	111	Prashad, M., et al., "Enzymatic resolution of ( $\pm$ )-threo-methylphenidate," <i>Tetrahedron: Asymmetry</i> , <b>1998</b> , <i>9</i> , 2133-2136	
	112	Prashad, M., et al., "Enantioselective synthesis of (2S,2'R)-erythro-methylphenidate," <i>Tetrahedron: Asymmetry</i> , <b>1999</b> , <i>10</i> , 3479-3482	
	113	Prashad, M., "The first enantioselective synthesis of (2R,2'R)-threo(+)-methylphenidate hydrochloride," <i>J. Org. Chem.</i> , <b>1999</b> , <i>64</i> , 1750-1753	
	114	Rochdi, M., et al., "Dose-proportional pharmacokinetics of a methylphenidate extended-release capsule," <i>Int. J. of Clin. Pharma. And Theraps.</i> , <b>2004</b> , <i>42</i> (5), 285-292	
/D.S./	115	Thai, D.I., et al., "Asymmetric synthesis and pharmacology of methylphenidate and its para-substituted derivatives," <i>J. Med. Chem.</i> , <b>1998</b> , <i>41</i> , 591-601	
<b>EXAMINER</b>	/Darryl Sutton/		<b>DATE CONSIDERED</b> 03/14/2008

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office			Docket No. CELG-0422		Application No. 10/820,397	
			Applicant Jerome B. Zeldis, et al.			
			Filing Date April 8, 2004		Group 1614	
			Confirmation No. 8455			
<b>U. S. PATENT DOCUMENTS</b>						
Examiner Initial		Document No.	Date	Name	Class	Subclass
/D.S./	116	5,773,478	06/30/98	Richards, et al.	514	649
	117	6,031,124	02/29/00	Fox, et al.	560	37
	118	6,113,879	09/05/00	Richards, et al.	424	9.1
	119	6,121,453	09/19/00	Zavareh	546	238
	120	6,242,464 B1	06/05/01	Harris, et al.	514	317
	121	6,344,215 B1	02/05/02	Bettman, et al.	424	459
	122	6,441,178 B2	08/27/02	Zavareh, et al.	546	238
	123	6,468,504 B1	10/22/02	Richards, et al.	424	9.1
	124	6,531,489 B2	03/11/03	Harris, et al.	514	317
	125	2002/0019535 A1	02/14/02	Zavareh, et al.	546	227
	126	2002/0032335 A1	03/14/02	Langston, et al.	546	238
	127	2003/0049205 A1	03/13/03	Richards, et al.	424	9.1
/D.S./	128	2003/0105134 A1	06/05/03	Harris, et al.	514	317
<b>EXAMINER</b>	/Darryl Sutton/			<b>DATE CONSIDERED</b>	03/14/2008	

**Form PTO-1449 Modified**

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
CELG-0422

Application No.  
10/820,397

Applicant  
Jerome B. Zeldis, et al.

Filing Date  
April 8, 2004

Group  
1614

Confirmation No.  
8455

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
/D.S./	129	WO 97/27176	07/31/97	PCT		
	130	WO 97/28124	08/07/97	PCT		
	131	WO 97/32851	09/12/97	PCT		
	132	WO 97/35836	10/02/97	PCT		
	133	WO 98/25902	06/18/98	PCT		
	134	WO 98/31668	07/23/98	PCT		
	135	WO 00/74680 A1	12/14/00	PCT		
	136	WO 01/43730 A3	06/21/01	PCT		
	137	0 958 281 B1	03/24/04	EPO		
	138	2 223 643 C	12/23/03	Canada		
	139	2 376 215 A1	12/06/01	Canada		
	140	589,625	01/18/45	Great Britain		
	141	788,226	12/23/57	Great Britain		
/D.S./	142	878,167	09/27/61	Great Britain		
<b>EXAMINER</b>			/Darryl Sutton/		<b>DATE CONSIDERED</b>	
					03/14/2008	